Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Unesbulin plus dacarbazine versus placebo plus dacarbazine in relapsed or refractory unresectable or metastatic leiomyosarcoma
NL-OMON53907Phase 2Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in leiomyosarcoma (LMS) comparing Unesbulin + dacarbazine with Placebo + dacarbazine (2 arms). Primary endpoint: Progression-free survival. Started Dec 2022; status: completed.
02
Drugs
unesbulin
03
Conditions
leiomyosarcoma (LMS)
Beyond the preview
Go deeper on NL-OMON53907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53907.